"Piperidines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of hexahydropyridines.
| Descriptor ID |
D010880
|
| MeSH Number(s) |
D03.383.621
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Piperidines".
Below are MeSH descriptors whose meaning is more specific than "Piperidines".
This graph shows the total number of publications written about "Piperidines" by people in this website by year, and whether "Piperidines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 1 | 0 | 1 |
| 1994 | 0 | 1 | 1 |
| 1995 | 0 | 2 | 2 |
| 1996 | 0 | 1 | 1 |
| 1997 | 0 | 1 | 1 |
| 1998 | 2 | 0 | 2 |
| 1999 | 3 | 0 | 3 |
| 2000 | 3 | 1 | 4 |
| 2001 | 0 | 2 | 2 |
| 2002 | 1 | 0 | 1 |
| 2003 | 2 | 1 | 3 |
| 2004 | 2 | 2 | 4 |
| 2005 | 3 | 1 | 4 |
| 2006 | 2 | 1 | 3 |
| 2007 | 1 | 6 | 7 |
| 2008 | 1 | 2 | 3 |
| 2009 | 0 | 4 | 4 |
| 2010 | 3 | 1 | 4 |
| 2011 | 3 | 1 | 4 |
| 2012 | 1 | 0 | 1 |
| 2013 | 4 | 2 | 6 |
| 2014 | 3 | 1 | 4 |
| 2015 | 2 | 0 | 2 |
| 2016 | 4 | 3 | 7 |
| 2017 | 6 | 2 | 8 |
| 2018 | 7 | 5 | 12 |
| 2019 | 4 | 4 | 8 |
| 2020 | 7 | 4 | 11 |
| 2021 | 8 | 7 | 15 |
| 2022 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Piperidines" by people in Profiles.
-
The dosing of ibrutinib and related Bruton's tyrosine kinase inhibitors: eliminating the use of brute force. Blood Adv. 2022 09 13; 6(17):5041-5044.
-
Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice. Clin Cancer Res. 2022 03 15; 28(6):1117-1126.
-
Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease. Br J Pharmacol. 2022 07; 179(13):3220-3234.
-
An evaluation of KBP-5074 in advanced chronic kidney disease with uncontrolled hypertension. Expert Opin Investig Drugs. 2021 Oct; 30(10):1017-1023.
-
Worldwide post-marketing safety surveillance experience with tofacitinib in ulcerative colitis. Aliment Pharmacol Ther. 2022 02; 55(3):302-310.
-
Body weight changes in patients with type 2 diabetes and a recent acute coronary syndrome: an analysis from the EXAMINE trial. Cardiovasc Diabetol. 2021 09 14; 20(1):187.
-
5-ASAs Combined With a Biologic or Tofacitinib: Predetermined Cost-Effectiveness? Am J Gastroenterol. 2021 09 01; 116(9):1958-1959.
-
Negative innovation: when patents are bad for patients. Nat Biotechnol. 2021 08; 39(8):914-916.
-
TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial. Gastroenterology. 2021 11; 161(5):1475-1486.
-
Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2. Science. 2021 08 20; 373(6557):931-936.